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Results and Discussion
Fig. S1 MALDI-TOF mass spectrum of C3-methylTert-amidated N-glycopeptides from standard IgG. "*" denotes the byproducts of IgG1 glycopeptides. For C3-methylTert compound, byproducts with additional 239.15 Da were obviously shown in the spectrum, and this side reaction was obviously with IgG1 glycopeptides. DMEN derivatization also had this side reaction, but it was much lower than C3-methylTert derivatization. After adding 1 L 1 M TEAB buffer to control the pH during DMEN derivatization, the side reaction was control and the byproducts were almost invisible. As for C2-Quat derivatization, since C2-Quat reagent carries a permanent positive charge, the derivatives couldn't be observed in the MALDI-MS (multi-charged) and the Byonic software need to be modified to recognize its fragments ion.
Fig. S2
Relative intensity ratio of an equimolar of IgG N-glycopeptides among different states. Relative intensity ratio of an equimolar mixture of IgG N-glycopeptides between dimethylated N-glycopeptides and native N-glycopeptides, DMEN-admidated N-glycopeptides and dimethylated N-glycopeptides in (a) MALDI-MS and (b) LC-ESI-MS analysis. In detail, equal amounts of native N-glycopeptides and dimethylated N-glycopeptides were combined together to HILIC enrichment and then MS analysis. The intensity (MALDI-MS) or XIC area (ESI-MS, +3 charge state) of the native N-glycopeptide and dimethylated N-glycopeptide were compared. Also equal amounts of dimethylated and DMEN-amidated N-glycopeptides were mixed together to HILIC enrichment, MS analysis and then compared. The ratio between DMEN-admidated N-glycopeptides and native N-glycopeptides were obtain from DMEN/dimethylation multiply by demethylation/native. 5+ at m/z 712.33. IgG2-G1, IgG3-G0F and IgG4-G0F are isomers, as [tyrosine + fucose] and [phenylalanine + Hexose] have the same mass. Thanks to the high ETD efficiency of this strategy, these N-glycopeptides can be well distinguished and identified. For example, c4 and z5 ions can be used to distinguish IgG2-G1 from IgG3-G0F, and z2, z3, z4 and c5, c6, c7 ions can be used to distinguish IgG2-G1 from IgG4-G0F.
Fig. S6
Workflow of isotopic dimethylation combined with DMEN-amidation for serum IgG N-glycopeptides quantitation. The normal serum from five healthy people were pooled before analysis for uniform standards and the serum from cirrhosis (CIR) and hepatocellular carcinoma (HCC) patients were analysis by individual, five cases respectively. For IgG1, IgG2 and IgG3/4 (grouped) N-glycopeptides, the relative abundance were calculated using the equation based on previous reports. 4 For IgG3/4 N-glycopeptides, the area of extracted ion chromatograms (XICs) of z5 were extracted manually for relatively quantifying IgG3 and IgG4 glycopeptodes (IgG3/IgG4 ratio), and then the XICs (after deconvolution) of precursor were divided into two part according IgG3/IgG4 ratio to quantify IgG3 or IgG4 glycopeptodes among different disease states. At last, the ratio of each IgG subclass N-glycopeptides to normal group were normalized to that the expression of their protein level based on their corresponding unique peptides (GPSVFPLAPSSK for IgG1, GLPAPIEK for IgG2, WYVDGVEVHNAK for IgG3 and GLPSSIEK for IgG4).
The affect of overlapping-peak was eliminated (deconvolution) based on previous reports and the calculated Sh: The area of XIC of monoisotope peak in the heavy labeled samples. (Table S2 ). In addition, for the N-glycopeptides from serum, the ratio was further were normalized to that the expression of their protein level based on its corresponding unique peptide.
For IgG3-G0F N-glycopeptide, the area of extracted ion chromatograms XICs(IgG3/4-G0F) were extracted and deconvolution described as above. After that, the XICs of z5 for IgG3-G0F and IgG4-G0F were extracted respectively in the light, medium and heavy sample to relative quantification of IgG3 and IgG4 glycopeptode, and then the XICs(IgG3/4-G0F)-light was divided into two parts by proportion. For instance, the relative ratio of z5 for
IgG3-G0F/IgG4-G0F in the light standard IgG sample was 0.53 (CV = 4.96%, n = 3), and then the XICs(IgG3/4-G0F)-light was divided into two parts, 35% for IgG3-G0F and 65% for IgG4-G0F, so as for middle and heavy labeled peaks. And the relative quantify of IgG3-G0F were under the formula, 35%*(SM-SL×(Sl+4/Sl)-SH×(Sh-
for SM/SL, and 35%*(SH-SL×(Sl+8/Sl)-SM×(Sm+4/Sm))/(35%*(SL-SM×(Sm-4/Sm) -SH×(Sh-8/Sh))) for SH/SL. 
Fig. S12
The distribution of precursors charge states in (a) all ETD MS/MS spectra and (b) all GPSMs (ETD and Byonic score≥ 150) from serum sample (n=3). Byonic score at a minimum of 150 was suggested for N-glycopeptides identified.
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Fig. S13
The number of N-glycopeptides identified from human serum (three technical repetitions). The highest score was used for the repeated identification of N-glycopeptides. The results were filtered to 1% FDR and Byonic score ≥150. [a] Ratios and CVs value were calculated by three repeated experiments, i.e. n = 3.
[b] ND stands for that N-intact glycopeptide was not quantified. 
